Amryt Pharma: files registration for listing on Nasdaq

24th June 2020 | Amryt Pharma plc

DUBLIN, Ireland, and Boston MA, June 24, 2020, Amryt Pharma (AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces that the Company has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) to facilitate the creation of a trading market in the United States for American Depositary Shares (“ADSs”). The Company is not proposing to register any new issuance of securities. The registration statement is subject to ongoing review by the SEC, and the proposed listing of ADSs representing the Company’s shares is subject to approval by Nasdaq.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. For the avoidance of doubt, the registration statement does not constitute a “prospectus” in the UK or in any member state of the European Economic Area (“EEA”) for the purposes of the Prospectus Regulation (Regulation (EU) 2017/1129) and has not been reviewed by any competent authority in the UK or in any member state of the EEA. No offer of securities to the public is being made in the UK or in any member state of the EEA.

Amryt Investor Videos

Amryt Investor Videos on Five Minute Pitch TV

Click here to view Amryt Investor Relations Videos